Stock Quote        
  Join        Login  
logo

Idenix Pharmaceuticals (IDIX) Prices 22M Share Offering At Discount

 August 02, 2012 10:07 AM
 

Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) has priced its public offering of 22 million shares at $8.00 apiece, a 4 percent discount to the stock's previous closing price.

The Cambridge, Massachusetts-based company, which is engaged in the development of drugs to treat human viral diseases, revised its collaboration agreement with its shareholder and Swiss pharmaceutical company Novartis (NYSE:NVS) earlier this week giving its increased flexibility to optimize the value of its pipeline.

The company agreed to pay Novartis a royalty based on worldwide sales of future Idenix hepatitis C drugs unless they are used in combination with drugs from Novartis. Idenix also announced on Tuesday it will no longer receive royalty or milestone payments from Novartis based upon sales of the hepatitis B treatment Tyzeka.

The companies also terminated an option right of Novartis to license Idenix's current and future development -stage drug candidates in any therapeutic area.

Idenix plans to use the net proceeds from the offering for research and development expenses relating to clinical trials of its drug candidates and potential acquisitions of new businesses.

The stock, which has been trading in the 52-week range of $4.06 to $15.25, fell 2.34 percent to $8.12 in early trade on Thursday.


Are you beating the market? We are!!!
Every trading day, be ready to attack the market instead of reacting to the market.

Subscribe to our premium newsletter - i On The Market


Two Week FREE Trial


Signup for i on the market daily edition


Advertisement

Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 




Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.